XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Dimitrios Pectasides,George Papaxoinis,Konstantine T. Kalogeras,Anastasia G. Eleftheraki,Ioannis Xanthakis,Thomas Makatsoris,Epaminondas Samantas,Ioannis Varthalitis,Pavlos Papakostas,Nikitas Nikitas,Christos Papandreou,George Pentheroudakis,Eleni Timotheadou,Angelos Koutras,Joseph Sgouros,Dimitrios Bafaloukos,George Klouvas,Theofanis Economopoulos,Konstantinos Syrigos,George Fountzilas

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

2012

Background The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer.

Keywords:

FOLFIRI
Bevacizumab
Capecitabine
Fluorouracil
Pathology
XELIRI
Colorectal cancer
Medicine
Surgical oncology
Irinotecan
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations